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Abstract
Background: Angioimmunoblastic T-cell lymphoma is one of the most common types of peripheral T-cell
lymphomas, usually presenting at an older age with an aggressive clinical course. Its characteristic morphological
presentation and follicular helper T-cell phenotype help to distinguish it from other T-cell lymphomas.
Case presentation: We recently encountered the unique case of a 63-year old patient with relapsed tumour-cell
rich angioimmunoblastic T-cell lymphoma, presenting with a “classical” phenotype and, in addition, an acquired,
strong, aberrant expression of CD20.
“Lineage infidelity” of phenotypic markers is a well-documented phenomenon in lymphomas and leukemias, a
circumstance currently still poorly understood and with the potential to bring about erroneous interpretations,
causing diagnostic havoc. This case represents one of the few documented angioimmunoblastic T-cell lymphomas
with strong CD20 expression. Of interest, CD20 expression was only detected in the recurrent lymphoma and not
upon initial diagnosis. The clinical importance of this finding lies in the potential for treatment with an anti-CD20
antibody, for instance Rituximab, in addition to standard chemotherapy protocols for angioimmunoblastic T-cell
lymphoma.
Conclusion: Diagnostic work-up of lymphomas to determine their lineage should therefore consider morphology,
pheno- as well as genotypic characteristics, where appropriate, and in particular signs of progression and change in
marker profile in relapsed cases e.g. acquisition of “non-lineage” markers such as CD20 in T-cell lymphoma.
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Background
Angioimmunoblastic T-cell lymphoma (AITL) repre-
sents one of the most common specific subtypes of per-
ipheral T-cell lymphomas, making up roughly 20% of all
cases [1]. The disease usually follows an aggressive
course, with poor overall survival of the mainly elderly
and frequently male patients [2]. The presentation and
immunophenotype is often very characteristic, typified
by effacement of the normal lymph node architecture by
a proliferation of small to medium-sized lymphocytes
with pale cytoplasm and minimal atypia intermingled
with a more or less pronounced non-neoplastic, reactive,
background infiltration of T-cells, B-cells, and plasma
cells, and often sparing the peripheral cortical sinuses.
Furthermore, an abundance of high endothelial vascular
structures as well as expanded follicular dendritic cell
meshworks are observed. The neoplastic cells present
with a follicular helper T-cell (TFH) phenotype with posi-
tivity for CD3, CD4, CD10, PD-1 and CXCL13 [3]. The
derivation of AITL from TFH may also explain the com-
monly observed expansion of B-cells in the setting of
angioimmunoblastic T-cell lymphoma, since these TFH
play a key regulatory role in the germinal center process-
ing of B cells [4].
Aberrant expression of so-called “lineage specific”
markers in lymphomas and leukaemias is a well-known
phenomenon and expression of CD20 in T-cell lymph-
omas is well documented [5]. However, we herein report
one of only very few published case observations of
CD20 expression in AITL and the second case ever of
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acquired CD20 expression in relapsed AITL. An aber-
rant and unexpected immunophenotype may lead to
substantial diagnostic difficulties. However this is also of
clinical importance, offering for instance the possibility
of an anti-CD20 therapy such as Rituximab in addition
to standard treatment protocols.
In the following, the authors discuss the case of re-
lapsed AITL presenting with an unusual tumour-cell rich
phenotype and aberrant CD20 expression upon relapse.
Case presentation
A 63-year old male patient presented with generalized
lymphadenopathy, exanthema, anasarca and overall
weakness in November 2011. His personal history was
remarkable for the diagnosis of a peripheral T-cell
lymphoma, not otherwise specified (NOS) seven years
prior (initial Ann Arbor stage IIA) and subsequent treat-
ment with eight cycles of chemotherapy (cyclophospha-
mide, hydroxydaunorubicin, oncovin and prednisone)
followed by 30 Gy involved-field irradiation of the in-
guinal region. He had been in complete remission since
completion of therapy. Currently, a diagnostic procedure
was performed, including an excisional lymph node bi-
opsy from the inguinal region.
Materials and methods
The reported data are represented in an irreversibly
anonymized manner and were obtained with the standard
diagnostic processes without additional tissue exhaustion,
according to the cantonal regulations. All research carried
out on the human tissue samples were in compliance with
the Helsinki Declaration. The excised lymph node tissue
was immediately fixed in 4% buffered formalin. Following
complete fixation, the sample was paraffin-embedded and
routinely stained with haematoxylin-eosin, Giemsa, Peri-
odic acid-Schiff ’s reaction and Novotny.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed,
paraffin-embedded serial tissue sections. For antigen re-
trieval, tissue sections were immersed and microwaved in
citrate buffer (pH 6.0) as appropriate for each antibody.
After rinsing with phosphate-buffered saline, immunohis-
tochemical analysis was performed using antibodies
against CD2, CD3, CD4, CD5, CD7, CD8, CD30, CD19,
CD20, CD79a, PAX-5, ALK1, PD-1 and CXCL13 (all anti-
bodies were from Ventana except CD19 (Dako) and
CXCL13 (R&D) and all were pre-diluted/ready to use, ex-
cept for CXCL13, which was diluted 1:50); respective
clones: MRQ11, 2GV6, SP35, SP19, SP94, SP57, L29,
LECD19, BerH2, SP18, SP34, ALK01, MRQ22 and poly-
clonal AF801). All staining was performed on an auto-
mated immunostainer (Benchmark XT from Ventana/
Roche, USA) using a streptavidin-biotin peroxidase
detection system, except for CXCL13, which was incu-
bated manually for 2 h at 37°C and also detected using a
streptavidin-biotin peroxidase detection.
For detection of Epstein-Barr virus-encoded RNA (EBER)
an in situ hybridization was performed on formalin-fixed,
paraffin-embedded tissue sections using the Ventana ready-
to-use kit as prescribed by the manufacturer.
Molecular pathology
To assess T- and B-cell clonality and clonal relationships
between the T-cell lymphomas diagnosed in 2004 and 2011
polymerase chain reaction (PCR) for both T-cell receptor
gamma and IgH heavy chain (IGH) was performed on
formalin-fixed, paraffin-embedded whole tissue sections.
Genomic DNA was extracted using a Genovison ex-
traction kit (Qiagen, Germany). Polymerase chain reac-
tion (PCR) based analysis for IGH gene rearrangements
was performed utilizing consensus FR1, FR3 and J
primers, as previously described [6]. The PCR products
were examined using a high-resolution fragment length
analyzer (ABI 310 Genetic Analyzer, Applied Biosystems/
Life Technologies, USA). Monoclonal gene rearrange-
ments were identified as prominent, single-sized amplifi-
cation products; the base pair length was recorded for
each fraction. A shift of the PCR products of more than
three base pairs between the cases was considered to indi-
cate a clonally unrelated event.
Histological findings
Regular histology revealed effacement of the normal
lymph node architecture by a vaguely nodular to diffuse,
tumour-cell rich lymphoid infiltrate with focal sparing of
peripheral cortical sinuses and destruction of the lymph
node capsule. An abundance of high endothelial venules
was noted (Figure 1A). The neoplastic cells consisted of
medium sized atypical lymphocytes with slightly eccentric-
ally located nuclei with coarse chromatin. The mitotic
count was elevated (>30/10 high power fields, HPF).
Immunohistochemical studies and in situ hybridization of
the current biopsy
Immunochemistry revealed the neoplastic cells to be of
a T-cell origin with positivity for CD2, CD3, CD4 and
CD5, expression of PD1 (moderate staining intensity)
and focal positivity for CXCL13 (Figure 1B-H); there was
antigenic loss for CD7. Furthermore the cells strongly and
diffusely expressed CD20, but no other B-cell markers
(CD79a, CD19 and PAX5), which stained intermingled re-
active small B-lymphocytes and scattered immunoblasts.
CD8 highlighted isolated non-neoplastic T-lymphocytes.
ALK1 and CD30 were negative. CD23 exposed expanded
follicular dendritic cell mesh works. EBER in situ hybridi-
zation did not reveal EBV infected tumour cells and only
isolated infected B-cells.
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Molecular pathology
Molecular pathology performed on the current lymph
node sample revealed a monoclonal T-cell population
based on T-cell receptor gamma fragment length analysis,
showing 191 base pairs length in two subsequent runs.
Retrospectively the same population was detected in the
initial lymph node biopsy obtained seven years previously,
suggesting a clonally related relapse (Figure 2). Cytogen-
etic analysis was not performed. B-cell clonality analysis
was performed in the initial biopsy as well as in the
follow-up biopsy after detection of CD20 expression in
the neoplastic population to exclude progression to or
concomitant existence of B-cell lymphoma. Clonal B-cells
were not detectable in either of the tested samples. At this
time point the diagnosis of relapsing AITL was made.
Despite the clear-cut positivity of the tumour cells for the
B-cell marker CD20, progression to frank B-cell lymph-
oma, which can be occasionally observed in AITL, could
be excluded taking into consideration histopathology and
phenotyping as well as results of the B-cell clonality
Figure 1 Hematoxylin and eosin (A) as well as immunochemical stainings (B-F) of the current lymph node biopsy from 2011.
Effacement of the normal lymph node architecture by medium-sized atypical lymphocytes. Evidence of expanded mesh works of follicular dendritic
cells stained by CD23 (B). Neoplastic cells show strong positivity for CD3 (C) and CD4 (D) as well as positivity for PD-1 (E) and CXCL13 (F).
Figure 2 Examination of the polymerase chain reaction (PCR)
for T-cell receptor gamma from DNA extracted from formalin-
fixed, paraffin-embedded whole tissue sections (current lymph
node as well as tissue from the initial diagnosis) using a high-
resolution fragment length analyser. Monoclonal gene
rearrangements are identified as prominent, single-sized
amplification products. This is seen in both samples, with a fragment
length analysis showing a “peak” (black arrow) at 191 base pairs
length in two subsequent runs, suggesting clonally-related relapse.
The bottom line (red) reveals the size of the fragment size.
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testing and in particular results from the T-cell clonality
analysis, which revealed an identical clone in the initial bi-
opsy as well as in the tumour relapse.
Retrospective immunohistochemical studies of the
initial biopsy
The initial lymph node biopsy was retrospectively ana-
lysed for the expression of CD20 in light of the suspected
lymphoma relapse. The initial biopsy showed features con-
sistent with AITL (expression of CD4, sparing of periph-
eral cortical sinuses, slightly expanded follicular dendritic
cell meshworks, abundance of high endothelial vascular
structures), the blasts were CD10-negative (PD1 and
CXCL13 were not yet available at the time of diagnosis in
our laboratory), so that the diagnosis of a peripheral T-cell
lymphoma, NOS was preferred at that time, which was
also in line with the lack of the typical biological AITL
syndrome, except for minimal exanthema. Retrospective
analysis showed presence of PD1- and partially CXCL13-
positive atypical cells in the initial biopsy. DNA extraction
and PCR-based T-cell receptor gamma fragment length
analysis revealed, as already mentioned, the same clonal
T-cell population in the initial biopsy as in the relapse.
Therefore the initial diagnosis was modified accordingly.
Careful comparison between the B-cell markers (CD20,
CD79a and PAX5) as well as the T-cell marker CD3 and
marker for TFH cells (PD-1) did not suggest co-expression
of CD20 on the neoplastic T-cells at the time of initial
diagnosis (Figure 3). Thus, we assume that expression of
CD20 was acquired by the AITL at the time of relapse. In
addition, morphological comparison between the initial bi-
opsy from 2004 and the biopsy from 2011 displayed a sig-
nificant increase in neoplastic cells in the latter compared
to the former, but no cytomorphological signs of progres-
sion such as the presence of frank anaplasia of the tumour
cells.
Conclusions
We report the case of relapsed AITL, which, in addition
to the “classical” follicular helper T-cell (TFH) phenotype
[3], displayed a striking expression of CD20. Whilst ex-
pression of CD20 has been reported in T-cell lymph-
omas [6], this case is one of only very few published
observations of CD20 expression in AITL and is unique
in that the CD20 expression was acquired upon relapse.
The first case of CD20-positive AITL was reported by
Yokose et al. as peripheral T-cell lymphoma with clinical
characteristics resembling angioimmunoblastic lymph-
adenopathy [7]. The second report was by Tachibana
et al. in 2011 [8] with features very similar to the herein
presented case, in particular also the acquisition of
Figure 3 Immunochemical stainings of the lymph node biopsy form 2011 (top row) as well as from the initial biopsy from 2004 (bottom
row). In the top row, PD-1 and CD20 equally mark the neoplastic T-cells, whilst staining for CD79a provides the contrast to CD20, highlighting the
sparse B-cell infiltrate. Only CD20-CD79a double positive cells represent B-cells, the (PD-1 positive) CD20 positive, CD79a negative cells effectively
represent the neoplastic T-cell population. In the initial lymph node biopsy in the bottom row retrospective PD-1 staining marks the neoplastic T-cells. In
contrast to the differing staining pattern in the top row, the CD20 and CD79a mark a different population of cells, namely an infiltrate of reactive B-cells.
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CD20 expression upon disease progression. Only re-
cently another case was observed by Foukas et al. [9].
Remarkable in our case is the clear-cut positivity of
the neoplastic T-cells for CD20, a B-cell marker, and the
progression from classical AITL in 2004 to tumour-cell
rich AITL in 2011. “Lineage infidelity” of phenotypic
markers is a well-documented phenomenon in lymph-
omas [10-13]. Although the biological mechanisms and
significance of this characteristic are poorly understood,
it has the potential to cause diagnostic havoc. Therefore
a multimodal approach that considers morphology,
pheno- and genotypic characteristics is essential to
achieve a final correct diagnosis. Hypothetically, CD20
positivity in T-cell lymphomas may include derivation
from subsets of CD20 positive T-cells undergoing neo-
plastic transformation or CD20-acquisition following
neoplastic transformation of the T-cells; the latter apply-
ing to our case, where CD20 was acquired upon relapse.
Indeed, CD20 expression may be acquired in T-cell
lymphomas following activation of the T-cells, as has
been demonstrated in stimulated lymph nodes from
monkeys with simian immunodeficiency virus [14]. This
experimental evidence is supported by the current case
as well as the series reported by Tachibana, Rahemtullah
and colleagues [5,8] where the proportion of CD20/
CD30 co-expressing T-cells increased over time. CD20
may therefore represent an “activation marker” acquired
after neoplastic T-cell transformation. Another possible
explanation for the observed CD20 acquisition may be
trogocytosis [15]. Upon interaction with surrounding
cells, lymphoid cells, especially CD8 positive cytotoxic
lymphocytes and NK-cells, can initiate membrane brid-
ges with target cells, thereby capturing small membrane
patches from their interaction partners and in the
process potentially acquiring “lineage-foreign” antigens
[16]. Since at least in our case there were no morpho-
logical hallmarks of cell cannibalism or signs of hemo-
phagocytosis, the AITL was of CD4 lineage and CD20
was the single “lineage-improper” antigen expressed by
the malignant cells, we speculate that trogocytosis might
not explain our observations.
Of clinical relevance is the possibility of targeting such
cases with Rituximab, a chimeric murine/human mono-
clonal antibody directed against the CD20 antigen. Cur-
rently, our patient was treated (off-study) with high dose
chemotherapy combining cisplatin with cytosine arabi-
noside and dexamethasone with addition of Rituximab
(R-DHAP). This treatment regimen lead to a partial re-
mission and the patient subsequently underwent autolo-
gous stem cell transplantation. However, the disease
relapsed only two months later and he succumbed to
sepsis in neutropenia upon salvage immunotherapy with
Lenalidomide in preparation for allogeneic stem cell
transplantation.
Treatment strategies incorporating the anti-CD20
antibody Rituximab have significantly improved results
in patients with mature B-cell lymphomas [17]. And
whilst Rituximab has been shown to suppress EBV-
positive B-immunoblasts in the microenvironment of
AITL [18], a recent small clinical trial revealed no
clear survival benefit of adding Rituximab to conven-
tional CHOP chemotherapy to target the intratumoral
B-cells [19].
Potential diagnostic difficulties and pitfalls in this case
were not only apparent because of the aberrant CD20
expression but also because of the unusual density of the
tumour cell infiltrate, resulting in morphological overlap
with peripheral T-cell lymphoma not otherwise specified
(PTCL, NOS). An important clue to the correct diagno-
sis of AITL – also in the initial biopsy – was the ex-
panded mesh works of follicular dendritic cells,
highlighted by the CD23 stain and the characteristic
phenotype with expression of TFH markers. The differ-
entiation between relapsed AITL with aberrant CD20
expression and AITL relapse as frank B-cell lymphoma,
a particular possibility in such instances, can be accom-
plished by testing for and comparing T- and B-cell
clonality both in the initial sample and upon relapse as
well as by evaluation of the immunohistochemical pro-
file of the neoplastic cells in serial sections.
Taken together this case highlights the spectrum by
which AITL can present. From the “classical” form readily
suspected in haematoxylin and eosin stains with a dis-
persed tumour-cell infiltrate sparing peripheral cortical
sinuses, with expanded follicular dendritic cell mesh works
and abundance of high endothelial vascular structures to
the more tricky form mimicking PTCL, NOS with dense
tumour-cell infiltrates, aberrant marker expression and
low numbers of EBV-positive B-cells. Correct classification
of peripheral T-cell lymphomas may become increasingly
important and in particular the diagnosis of PTCL, NOS
should not be used as a “waste basket” for tricky cases. In-
creasingly molecular profiling provides evidence that dif-
ferent pathways are primarily involved in different subsets
of T-cell lymphomas. Indeed, as is the case with AITL, in
which activation of the NF-κB pathway appears to be of
importance [20], such new insights may even lead to more
tailored treatment options in the future, including the use
of inhibitors of the NF-κB pathway in AITL.
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